[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address 54.166.89.187. Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Evidence to Practice
July 9, 2012

Comparative Effectiveness of Anti–Growth Factor Therapies for Diabetic Macular EdemaSummary of Primary Findings and Conclusions

Author Affiliations

Author Affiliation: Department of Medicine, Uniformed Services University, Bethesda, Maryland.

Arch Intern Med. 2012;172(13):1014-1015. doi:10.1001/archinternmed.2012.2335

Diabetic macular edema (DME) is a common consequence of diabetic retinopathy and a leading cause of significantly impaired vision among patients with diabetes. For many years, the standard of care has been to treat DME with laser photocoagulation treatments to the macula. Recently, evidence has begun to accumulate demonstrating the effectiveness of injectable intravitreal drugs that inhibit vascular endothelial growth factor (VEGF). Although none of these agents has yet received Food and Drug Administration approval for this indication, off-label use is substantial. The objective of this review was to assess the clinical effectiveness and potential harms of all available anti-VEGF drugs: pegaptanib (Macugen), bevacizumab (Avastin), ranibizumab (Lucentis), and aflibercept (Eylea).

First Page Preview View Large
First page PDF preview
First page PDF preview
×